Organigram Global Inc.
NASDAQ:OGIDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $95.40M
- Beta
- 1.84
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$0.19
Volume 0.62M
Average 0.67M
OGI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Organigram Global Inc.NASDAQ: OGI
Stock-Based Compensation · Q2 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of CA$728K fell 22.4% year over year, ahead of the -36.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 5.5% from the prior quarter.
Context
- Stock-based compensation amounted to 2.3% of revenue in FY2025, down 2.2 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -22.4% holds above the trailing-twelve-month pace of -36.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
CAD · from the cash flow
- Latest · FY2025
- 4.22M CAD
- Year-over-year change
- -41.3%
- 4-year CAGR
- +2.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 4.22M | -41.3% |
| FY2024 | 2024-09-30 | 7.18M | +35.9% |
| FY2023 | 2023-09-30 | 5.29M | +3.1% |
| FY2022 | 2022-08-31 | 5.13M | +31.6% |
| FY2021 | 2021-08-31 | 3.9M | — |
Stock-Based Compensation vs competitors
How OGI compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -36.6% is the 8th highest of 9, against a peer median of +3.7%.
- Stock-based compensation amounts to 1.3% of revenue for OGI, versus a peer median of 9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €26.77M EUR | +647.7% | +129.4% | 597.1% | |
| LTM Mar 2026 | $11.86M USD | +7.9% | +52.0% | 36.3% | |
| LTM Mar 2026 | $10.44M USD | +36.3% | -2.0% | 587.9% | |
| LTM Mar 2026 | $8.72M USD | +217.8% | — | 90.9% | |
| LTM Mar 2026 | CA$7.29M CAD | -36.7% | -24.4% | 2.3% | |
| LTM Mar 2026 | $5.95M USD | -1.0% | +12.4% | 9.2% | |
| LTM Mar 2026 | $5.91M USD | — | +57.3% | 4.4% | |
| LTM Mar 2026 | $4.49M USD | -0.5% | +4.5% | 3.2% | |
| LTM Mar 2026 | CA$3.45M CAD | -36.6% | — | 1.3% | |
| LTM Mar 2026 | $2.61M USD | -8.5% | +46.3% | 3.6% | |
| Peer median (excluding OGI) | — | +3.7% | +29.4% | 9.2% | |
Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Aug 2021 | FY2022 Aug 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (130.7M) | (14.28M) | (229.48M) | (45.44M) | (24.76M) |
| Depreciation & Amortization | 31.03M | 24.91M | 24.08M | 12.08M | 17.98M |
| Deferred Income Tax | 42.21M | (88K) | (2.66M) | 0 | (13.77M) |
| Stock-Based Compensation | 3.9M | 5.13M | 5.29M | 7.18M | 4.22M |
| Change in Working Capital | 24.2M | (22.88M) | 12.51M | 14.96M | (2.12M) |
| Accounts Receivables | (6.01M) | (24.02M) | 12.51M | (12.06M) | (15.29M) |
| Inventory | 28.68M | (12.22M) | 0 | 0 | 0 |
| Accounts Payables | 2.06M | 12.15M | 0 | 0 | 0 |
| Other Working Capital | (542K) | 1.21M | (4.06M) | 27.02M | 13.16M |
| Other Non-Cash Items | 776K | (29M) | 151.8M | 15.09M | 14.16M |
| Operating Cash Flow | (28.59M) | (36.21M) | (35.8M) | 3.87M | (4.3M) |
| Capital Expenditures | (12.33M) | (48.78M) | (26.9M) | (5.34M) | (12.22M) |
| Acquisitions (Net) | (2.54M) | (11.06M) | 0 | 0 | (65.62M) |
| Purchases of Investments | (120.02M) | (15M) | (7.36M) | (29.24M) | (1.01M) |
| Sales of Investments | 50.85M | 114.59M | 36.37M | 3.52M | 2.5M |
| Other Investing Activities | (31.08M) | 4.29M | 31.46M | (8.32M) | 21.8M |
| Investing Cash Flow | (115.11M) | 44.03M | 4.56M | (38.77M) | (59.35M) |
| Debt Repayment | (116.4M) | (1.01M) | (64.04K) | (786K) | (43.08K) |
| Common Stock Issued | 284.88M | 6.34M | 20K | 108.56M | 29.57M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.99M | 6.34M | (754.15K) | 6K | (1.29M) |
| Financing Cash Flow | 174.46M | 5.33M | (754.15K) | 107.78M | 28.24M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (2.57M) |
| Net Change in Cash | 30.77M | 13.15M | (68.52M) | 72.88M | (37.98M) |
| Free Cash Flow | (40.92M) | (84.99M) | (62.7M) | (1.47M) | (16.52M) |
Organigram Global Inc.
NASDAQ:OGI
Intrinsic Alpha fair value
Locked
Current Price
$0.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.